Akari Therapeutics, Plc
AKTX
$10.92
-$0.04-0.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.81M | 8.74M | 9.28M | 10.19M | 9.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.68M | 12.20M | 12.10M | 13.16M | 12.79M |
| Operating Income | -13.68M | -12.20M | -12.10M | -13.16M | -12.79M |
| Income Before Tax | -32.82M | -29.91M | -18.30M | -16.86M | -12.27M |
| Income Tax Expenses | -1.86M | -1.86M | -1.00M | -1.09M | -- |
| Earnings from Continuing Operations | -30.96 | -28.05 | -17.30 | -15.77 | -12.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.96M | -28.05M | -17.30M | -15.77M | -12.27M |
| EBIT | -13.68M | -12.20M | -12.10M | -13.16M | -12.79M |
| EBITDA | -5.44M | -8.56M | -12.08M | -13.15M | -12.78M |
| EPS Basic | -2.01M | -1.99M | -1.65M | -1.88M | -2.01M |
| Normalized Basic EPS | -5.28 | -6.06 | -8.09 | -11.11 | -13.22 |
| EPS Diluted | -2.01M | -1.99M | -1.65M | -1.88M | -2.01M |
| Normalized Diluted EPS | -5.28 | -6.06 | -8.09 | -11.11 | -13.22 |
| Average Basic Shares Outstanding | 5.17M | 4.17M | 3.37M | 2.77M | 2.26M |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |